Inhibitor Therapeutics, Inc. Quarterly Debt-to-equity in % from Q3 2015 to Q2 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Inhibitor Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q3 2015 to Q2 2024.
  • Inhibitor Therapeutics, Inc. Debt-to-equity for the quarter ending June 30, 2024 was 63.4 %, a 12.6% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q2 2024 63.4 -9.11 -12.6% Jun 30, 2024
Q1 2024 55.4 -126 -69.5% Mar 31, 2024
Q4 2023 48.7 +506 Dec 31, 2023
Q3 2023 43.8 +145 Sep 30, 2023
Q2 2023 72.6 +174 Jun 30, 2023
Q1 2023 182 +284 Mar 31, 2023
Q4 2022 -458 -355 -344% Dec 31, 2022
Q3 2022 -101 +2.17 +2.09% Sep 30, 2022
Q2 2022 -102 +2.04 +1.97% Jun 30, 2022
Q1 2022 -102 +1.99 +1.91% Mar 31, 2022
Q4 2021 -103 +3.53 +3.31% Dec 31, 2021
Q3 2021 -104 +9.73 +8.59% Sep 30, 2021
Q2 2021 -104 +24.5 +19.1% Jun 30, 2021
Q1 2021 -104 +53.2 +33.8% Mar 31, 2021
Q4 2020 -107 +87.2 +45% Dec 31, 2020
Q3 2020 -113 +157 +58% Sep 30, 2020
Q2 2020 -128 +28.5 +18.2% Jun 30, 2020
Q1 2020 -158 -74.5 -89.6% Mar 31, 2020
Q4 2019 -194 -142 -273% Dec 31, 2019
Q3 2019 -270 -229 -554% Sep 30, 2019
Q2 2019 -157 -14.7 -10.4% Jun 30, 2019
Q1 2019 -83.1 -160 -208% Mar 31, 2019
Q4 2018 -52 -81.8 -274% Dec 31, 2018
Q3 2018 -41.3 -51.9 -489% Sep 30, 2018
Q2 2018 -142 -152 -1463% Jun 30, 2018
Q1 2018 77 +66.5 +635% Mar 31, 2018
Q4 2017 29.9 +15 +101% Dec 31, 2017
Q3 2017 10.6 -18.8 -63.9% Sep 30, 2017
Q2 2017 10.4 -33.3 -76.2% Jun 30, 2017
Q1 2017 10.5 -64.3 -86% Mar 31, 2017
Q4 2016 14.9 -56.8 -79.3% Dec 31, 2016
Q3 2016 29.4 -50.4 -63.1% Sep 30, 2016
Q2 2016 43.7 Jun 30, 2016
Q1 2016 74.7 Mar 31, 2016
Q4 2015 71.6 Dec 31, 2015
Q3 2015 79.9 Sep 30, 2015
* An asterisk sign (*) next to the value indicates that the value is likely invalid.